Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Craniofacial development protein 1 (CFDP1)
- Target
- CFDP1
- Molecular classification
- Chromatin-associated protein, Chromatin remodeling complex subunit, Phosphoprotein, Other (it is not a receptor, ion channel, transporter, or classical enzyme; best classified as chromatin/chromatin remodeling complex protein)
01
Overview
Craniofacial development protein 1 (CFDP1) is an evolutionarily conserved chromatin-associated protein essential for cell division, chromatin organization, and embryonic development. It binds chromatin and interacts with chromatin remodeling complexes, notably the SRCAP complex, to regulate histone dynamics, chromatin structure, and condensin recruitment. CFDP1's stability is crucial for centromeric heterochromatin integrity, impacting chromosome segregation and cell cycle progression. Mutations or disruptions can cause severe developmental disorders, especially affecting craniofacial and cardiac formation. The protein's biological function is tightly regulated by phosphorylation and acetylation, and it is expressed in numerous human tissues beyond the craniofacial region, demonstrating wide developmental importance
- Other names
- BCNTBucentaurCENP-29CP27SWC5Yetip97Craniofacial development protein 1 (full name)BUCENTAURcentromere protein 29phosphoprotein (Bucentaur)
02
Mechanism of action
Restoration or stabilization of heterochromatin architecture and centromere integrity; Modulation of epigenetic chromatin state or histone variant loading (e.g., through SRCAP complex regulation)
03
Biological functions
Chromatin remodeling and organizationHeterochromatin stabilityCell division (mitosis)Cell cycle progressionCellular proliferationRegulation of gene transcription (via interactions with SMAD3 and other transcriptional regulators)Neural and craniofacial development
04
Disease associations
Developmental disorders (including Amelogenesis imperfecta, Floating-Harbor syndrome, birth defects)Cardiac development/defects in animal modelsCraniofacial malformations (mouse and human studies)Other: likely roles in general chromatinopathies and proliferation/disorder mechanisms due to its central role in cell division
05
Safety considerations
Disruption of CFDP1 leads to chromosome segregation abnormalities and major developmental defects in animal modelsTargeting CFDP1 for therapy would risk adverse effects on cell proliferation, genome stability, and organogenesisCentral role in cell cycle highlights inherent safety/therapeutic challenges
Beyond the preview
Go deeper on Craniofacial development protein 1 (CFDP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Craniofacial development protein 1 (CFDP1).